Article info
PDFExtended essay
A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial
- Correspondence to Alexander Masters, alexander.masters{at}btopenworld.com
Citation
A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial
Publication history
- Received November 15, 2016
- Revised March 2, 2017
- Accepted March 29, 2017
- First published June 6, 2017.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Other content recommended for you
- Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
- Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
- Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
- Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
- Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma
- CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
- Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
- Acceptability of donor funding for clinical trials in the UK: a qualitative empirical ethics study using focus groups to elicit the views of research patient public involvement group members, research ethics committee chairs and clinical researchers
- Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
- Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy